Avalo Therapeutics (AVTX) Gross Profit (2017 - 2024)

Avalo Therapeutics (AVTX) has 8 years of Gross Profit data on file, last reported at -$465000.0 in Q3 2024.

• Quarterly Gross Profit fell 4127.27% year-over-year to -$465000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was -$96000.0 (down 177.42% YoY) and the FY2023 annual result came in at $640000.0, down 95.62% from the prior year.
• Gross Profit retreated to -$465000.0 in Q3 2024, from -$343000.0 in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $14.4 million in Q3 2022 to a low of -$534000.0 in Q2 2022.
• A 5-year average of $1.3 million and a median of $396000.0 in 2021 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit surged 3162.67% — and 2024, when it plunged 4127.27%.
• Tracing AVTX's Gross Profit over 5 years: stood at $1.4 million in 2020, then tumbled by 114.46% to -$205000.0 in 2021, then soared by 234.63% to $276000.0 in 2022, then jumped by 186.96% to $792000.0 in 2023, then tumbled by 158.71% to -$465000.0 in 2024.
• The last three Gross Profit figures came in at -$465000.0 (Q3 2024), -$343000.0 (Q2 2024), and -$80000.0 (Q1 2024), per Business Quant data.